Navigation Links
MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, announces today that it has successfully completed the installation and qualification of a new Xevo® TQ-S tandem mass spectrometer from Waters Corporation. The unparalleled speed, sensitivity and accuracy of this new LC/MS/MS system will allow MicroConstants to quantify compounds at lower concentrations than previously possible and enable the development of more robust bioanalytical methods for even the most analytically complex compounds.

The Xevo® TQ-S tandem mass spectrometer was released in September of 2010 and this state-of-the-art LC/MS/MS system further increases the high sensitivity provided by the previous model, the Xevo® TQ MS, which MicroConstants acquired last June. The addition of this new system brings MicroConstants equipment count to a total of 16 LC/MS/MS systems at their San Diego bioanalytical laboratory.

When compared to earlier generation mass spectrometer models, MicroConstants experienced a forty fold increase in sensitivity with compounds tested internally in negative electrospray ionization mode. The significant increase in sensitivity can be attributed primarily to the system's new StepWave™ ion-transfer technology. This off-axis design dramatically increases the efficiency of ion transfer from the ion source to the quadrupole MS analyzer while at the same time actively eliminating undesirable neutral contaminants.

"Over the years, MicroConstants has gained a reputation for having the ability to develop bioanalytical methods for complex compounds when others have been unsuccessful in doing so," said David Beyerlein, vice president of global operations at MicroConstants. "This new LC/MS/MS system will allow our innovative method development team to improve methods and speed up method development for analytically complex compounds to help advance our clients' drug development programs."

About MicroConstants, Inc.

MicroConstants is a specialty Contract Research Organization (CRO) in San Diego, California that provides GLP-compliant bioanalytical research services, IND-enabling drug metabolism (DMPK) assays, ELISA immunoassay and pharmacokinetic analysis services to pharmaceutical and biotech companies developing new chemical entities worldwide. They specialize in method development, method validation and sample analysis of small molecules, proteins and peptides using LC/MS/MS, HPLC/UV and ELISA for preclinical and clinical drug development studies. For more information about MicroConstants and the contract research services they provide, please visit http://www.microconstants.com.


'/>"/>
SOURCE MicroConstants, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants Now Offers Nanoparticle Formulation Services
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
Breaking Medicine News(10 mins):